A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs

Eisai Alzheimer Drug Shows Promise in Injected-At-Home Form

Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal

Eisai’s Alzheimer’s Drug Wins Approval in Japan, Following US

Eisai Azheimer’s Drug Set to Win Japanese Approval, Following US

Broadcom Secures $28.4 Billion Debt Financing for VMware Buy

Sanofi Was Mystery Bidder That Lost Reata to Biogen 

Sage Tumbles as Depression Pill Approval Omits Major Disorder

Women Hold a Third of S&P 500 Boards Seats With Gains in June

Biogen to Buy Reata for $7.3 Billion in Rare-Disease Expansion

Medicare Proposes Expanding Patient Access to Alzheimer’s Scans

Lilly Applies for Alzheimer’s Drug’s US Approval After Trial Success